A bankruptcy declaration and large settlement are supposed to bring some degree of closure. Purdue Pharma LP’s bankruptcy filing and $10 billion plan to settle litigation over its alleged role in fueling the opioid crisis, announced Sept. 15, may not provide much. The proposal from Purdue, which made billions selling the highly popular opioid OxyContin,…
You must be a paid subscriber to read this content.
To keep reading and receive unlimited access subscribe today for only $1.
Subscribe Now
Already a Subscriber?
Login now
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
